Bortezomib (PS-341)

For research use only.

Catalog No.S1013 Synonyms: LDP-341, MLM341

533 publications

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 127 In stock
USD 270 In stock
USD 670 In stock
USD 1370 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Bortezomib (PS-341) has been cited by 533 publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MUfDfZRwfG:6aXOgRZN{[Xl? M3\RNVUxKM7:TR?= MVy0PEBp MUPEUXNQ M3nZUmtqdGy|IHPlcIx{KGK7IH3vdoUhfGijbjC5PUU> MXOxNFQ6QTZ2Mx?=
OVCA 429 NGnzNlFHfW6ldHnvckBCe3OjeR?= NFvBZlk{ODBibl2= NVjSbJRKPDhiaB?= M3;ybGROW09? MUDEbZNzfXC2czDpcpRi[3RibYXseIlk\WyudXzhdkB1fW2xcjDzdIhmem:rZIO= Mmr1NVA6QTl5Nk[=
RPMI8226 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPwbHNQOTByIH7N M4XQRlQ5KGh? NYKzUZB3TE2VTx?= NWP6UYpZUUN3ME2zNEBvVQ>? NYTDZYxLOTF|ME[0PFk>
Dox40 NGjRTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTG[JJiOTByIH7N MYO0PEBp MVzEUXNQ MVfJR|UxRTRyIH7N NXTJW283OTF|ME[0PFk>
MR20 M3\PSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLlSY4yODBibl2= MnX6OFghcA>? MUDEUXNQ MWPJR|UxRTJyIH7N NEXVNHgyOTNyNkS4PS=>
LR5 NVjjSJRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjPcItTOTByIH7N MlHpOFghcA>? NVHYbWpITE2VTx?= NU\ObHdnUUN3ME2yNEBvVQ>? MYixNVMxPjR6OR?=
U266 Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTtNVAxKG6P MYe0PEBp NFmzPGJFVVOR NVrMS3g3UUN3ME2zJI5O NGrTboUyOTNyNkS4PS=>
IM-9 NXjoRYYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnENlIyODBibl2= NH;Rb2c1QCCq M{PZRmROW09? MnO5TWM2OD14IH7N MlfkNVE{ODZ2OEm=
Hs Sultan M2foOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfTNVAxKG6P M3vqNFQ5KGh? M1nRV2ROW09? NI\NOZZKSzVyPUKwJI5O MX6xNVMxPjR6OR?=
PAM-LY2 NIHLRnBHfW6ldHnvckBCe3OjeR?= MWqxNFAhdk1? MUixNkBp M3fpSmROW09? MmfyTY5pcWKrdIOgUmYu|rqEIHHjeIl3[XSrb36= NGXue3cyOTN3MEmxNy=>
PAM 212 MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH32c3gyODBibl2= NIX6UWY4OiCq NY[zdo5GTE2VTx?= M4\ZbmlvcGmkaYTzJINmdGxidnnhZoltcXS7 MVmxNVM2ODlzMx?=
PAM-LY2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnnfoxXOTByIH7N NHTGXI44OiCq NIribpJFVVOR MonrTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M1zDSVEyOzVyOUGz
B4B8 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TCclExOCCwTR?= MnHRO|IhcA>? NFfIXHpFVVOR Mn70TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M4q2clEyOzVyOUGz
B7E3 NW\tfIZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWOzVnd[OTByIH7N MmL2O|IhcA>? MWPEUXNQ NGDYepBKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MkC1NVE{PTB7MUO=
UM-SCC-9 NVTuU2JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGxNFAhdk1? MVS3NkBp M1HROmROW09? MYXJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M2j5SlEyOzVyOUGz
UM-SCC-11B Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO0dZFLOTByIH7N NXTEZ3F3PzJiaB?= MonsSG1UVw>? NIfYZ|ZKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MWSxNVM2ODlzMx?=
H460 M375NGZ2dmO2aX;uJGF{e2G7 NHz3XlYyOCEQvF2= NV3NeoR2OjRiaB?= NUfh[5ZsTE2VTx?= NHT4XFJKdmS3Y3XzJGJkdC1{IIDoc5NxcG:{eXzheIlwdiCjbnSgZ4xm[X[jZ3WgZ49zemWuYYTl[EB4cXSqIFeyMW0heGijc3WgZZJz\XO2 M3y4NFEzPDl{MUG3
U266 NV;zeIhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDkfIlkPTByIH7nM41t M4fWZVQ5KGh? M2jyfmROW09? Mk\jTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MYexNlY{OTZzOR?=
ARH77 M3PjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzYOVAxKG6pL33s MoXkOFghcA>? NFv5ZVhFVVOR M{jIdGlvcGmkaYTzJINmdGxiZ4Lve5Rp NYDNWI1yOTJ4M{G2NVk>
WAD-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1myb|UxOCCwZz;tcC=> NEnTfWI1QCCq MYLEUXNQ MlnpTY5pcWKrdIOgZ4VtdCCpcn;3eIg> M2rX[|EzPjNzNkG5
U266/LR7 NITzW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPrU3I2ODBibnevcYw> MlzIOFghcA>? NE\pNmtFVVOR MX\Jcohq[mm2czDj[YxtKGe{b4f0bC=> MV[xNlY{OTZzOR?=
U266/dox4 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWW1NFAhdmdxbXy= M4S4dVQ5KGh? NVzic2R4TE2VTx?= NULje2tWUW6qaXLpeJMh[2WubDDndo94fGh? NHLBfmwyOjZ|MU[xPS=>
RPMI8226/LR5 NYnlcoMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXq1NFAhdmdxbXy= NYTYbFFUPDhiaB?= NWe4[5NzTE2VTx?= MnLjTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NUDCNWRGOTJ4M{G2NVk>
H460 MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjmfo4yOCEQvF2= M1eyXlczKGh? M2PQZWROW09? M{e4ZmlEPTB;MUCwJI5O NULzVm1XOTJ4M{G2NlA>
H358 M13pdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\TbIkyOCEQvF2= NHvEXII4OiCq MoXwSG1UVw>? MVfJR|UxRTdyIH7N MojNNVI3OzF4MkC=
H322 NGiySndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LHU|ExKM7:TR?= M2P3TlczKGh? NGnTfZhFVVOR NEPORYhKSzVyPU[yNEBvVQ>? NW\2WXlZOTJ4M{G2NlA>
H460 Mlq5SpVv[3Srb36gRZN{[Xl? MYqxNFAhdk1? NGG1[XozPCCq M2\pSmROW09? NWT3VotTUW6mdXPld{BIOi2PLYDoZZNmKGG{cnXzeEBidmRidIXieYxqdiCjc4PlcYJtgS2maYPhd5NmdWKueR?= MVuxNlY{OTZ{MB?=
LNCap-Pro5 NUDxTVc1TnWwY4Tpc44hSXO|YYm= MonYNUDPxE1? NInPSXo1KGh? MV\EUXNQ NF7JbpJUfGGkaXzpfoV{KHB3Mx?= NX7CN3ZbOTR4MUK1N|I>
T29 MWHBdI9xfG:|aYOgRZN{[Xl? MVy1NEBvVQ>? M3XS[|Q5KGhi M3jocWROW09? MkPtTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NVXMcpN{OTZ5N{ixO|k>
T29Kt1 NYThSII4SXCxcITvd4l{KEG|c3H5 MV21NEBvVQ>? M33LZ|Q5KGhi M3PrPGROW09? MYnJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVqxOlc4QDF5OR?=
HCT116 NFLoR29CeG:ydH;zbZMhSXO|YYm= NXHaZYJPPTBibl2= Mnf0OFghcCB? Mn\hSG1UVw>? MYTJcoR2[2W|IHPlcIwh[XCxcITvd4l{ Ml61NVY4PzhzN{m=
HKe-3 MnnFRZBweHSxc3nzJGF{e2G7 MmT4OVAhdk1? M2TQXlQ5KGhi MYfEUXNQ NHfleIZKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MWmxOlc4QDF5OR?=
NB-1691 NHznS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKxJO69VQ>? MnLoO|IhcA>? NF:4fHVKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW= MXSxO|Y5QTZ6NB?=
CHLA-255 MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnyxNUDPxE1? MnntO|IhcA>? M3H3c2lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB{JR?= MUmxO|Y5QTZ6NB?=
SK-N-AS MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDzNUDPxE1? MXK3NkBp MV\Jcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOTBn NV;vW3Y2OTd4OEm2PFQ>
NB-1691 NWi2fpdITnWwY4Tpc44hSXO|YYm= NGjJNJIyOCCwTR?= MXqyOEBp Mn;jV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KGOnbHzzJIlvKHSqZTDHNE9IOSCyaHHz[S=> M1L5dVE4Pjh7Nki0
CHLA-255 M3rrOmZ2dmO2aX;uJGF{e2G7 Mni1NVAhdk1? M3HzeVI1KGh? M1;NeG1w\GW|dHz5JJJm\HWlZYOgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOn M4LSZVE4Pjh7Nki0
RPMI 8226 NIPKeWpHfW6ldHnvckBCe3OjeR?= MUeyNEBvVQ>? M1j2elghcA>? M3mzNXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MWexPVQ{PjB3MB?=
MM.1S MVnGeY5kfGmxbjDBd5NigQ>? MWOyNEBvVQ>? NWKxTpBqQCCq Mn:wV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> Mo\wNVk1OzZyNUC=
U266 NIjFV|VHfW6ldHnvckBCe3OjeR?= NGT3OHAzOCCwTR?= MV:4JIg> MmrBV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MUWxPVQ{PjB3MB?=
OPM1 NEHBUYRHfW6ldHnvckBCe3OjeR?= M4PKe|IxKG6P NFS1N2k5KGh? MnrsV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MWixPVQ{PjB3MB?=
INA6 Mn;hSpVv[3Srb36gRZN{[Xl? MUmyNEBvVQ>? NH3hWpo5KGh? M4K0b3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MnLjNVk1OzZyNUC=
OPM2 NXvYWJAxTnWwY4Tpc44hSXO|YYm= NHyxb20zOCCwTR?= Ml;oPEBp MoDSV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MknCNVk1OzZyNUC=
RPMI 8226 NFn5OFhHfW6ldHnvckBCe3OjeR?= NFfPbGkzOCCwTR?= MoXkPEBp NGW1bGlKdmS3Y3XzJGRPSSC|eX70bIV{cXN? MYexPVQ{PjB3MB?=
BaF/3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O1dVExOCCwTR?= NXXUVGNWPDhiaB?= MknPTWM2OD14LkKgcm0> M4TWSFIxOzB3Nkmy
BaF/3-p210 MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjZT2FuOTByIH7N MWm0PEBp MnfnTWM2OD12Lkegcm0> MU[yNFMxPTZ7Mh?=
TCC-S NUTZb|U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:xdlk4OTByIH7N NVTneJlXPDhiaB?= MXTJR|UxRTJwODDuUS=> Mnm0NlA{ODV4OUK=
BaF/3 Ml:0SpVv[3Srb36gRZN{[Xl? M4riUlYhdk1? MX20PEBp NU\aWo1tUW6mdXPld{BiKGe{ZXH0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 M{TGVlIxOzB3Nkmy
BaF/3-p210 NFm5RWRHfW6ldHnvckBCe3OjeR?= MYi2JI5O NXLmOYZwPDhiaB?= MoTHTY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> NG\IfVAzODNyNU[5Ni=>
BaF/3-p210 NHLMNGxHfW6ldHnvckBCe3OjeR?= M4XNUVYhdk1? MkfqNlQhcA>? MojqVoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJIFv\CC2aHWgZYN1cX[rdImgc4YhWmJ? NEX0c28zODNyNU[5Ni=>
Raji NXH0do9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnyVlhDOSEQvF2= MYeyOEBp M1;Xb3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MnnQNlEyPzB7OEi=
LCL-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\mTGEyKM7:TR?= MkLXNlQhcA>? NHrWcmpT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NGXLPXYzOTF5MEm4PC=>
LCL-2 NH\4OGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\YZVEh|ryP MlrDNlQhcA>? Mk[3VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NILTc40zOTF5MEm4PC=>
BJAB NWKyUnhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWCxJO69VQ>? NUS1dZduOjRiaB?= M{DadXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MYGyNVE4ODl6OB?=
SNT-13 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVixJO69VQ>? NUHzTY13OjRiaB?= NXK0PJpFWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NUn1ellFOjFzN{C5PFg>
SNT-16 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW4NUDPxE1? Ml;DNlQhcA>? M2LPSXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NXO3VFhwOjFzN{C5PFg>
Jurkat NWDLNmtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUmyWFUzOSEQvF2= MYmyOEBp M1z1RXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M3vrdlIyOTdyOUi4
KAI-3 MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\HWYVxOSEQvF2= Mli0NlQhcA>? MYTS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NFvEWlczOTF5MEm4PC=>
SNK-6 MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe4fVEyKM7:TR?= MVuyOEBp NHrk[2RT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NXTvV4dSOjFzN{C5PFg>
KHYG-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fDdlEh|ryP M2j2UlI1KGh? Ml[1VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MX2yNVE4ODl6OB?=
SNT-16 MUTBdI9xfG:|aYOgRZN{[Xl? MVKxJO69VQ>? MYe2JIg> NEOy[pFKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MoDtNlEyPzB7OEi=
Jurkat MkXCRZBweHSxc3nzJGF{e2G7 NHLycFEyKM7:TR?= MnTHOkBp NFvydoxKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NELHRYYzOTF5MEm4PC=>
KAI-3 MV7BdI9xfG:|aYOgRZN{[Xl? MWexJO69VQ>? MXK2JIg> NUj1TWN6UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NEPwVmgzOTF5MEm4PC=>
KHYG-1 NG\qdW9CeG:ydH;zbZMhSXO|YYm= NEDuWJoyKM7:TR?= MWq2JIg> NYj4NXdRUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NELxTHczOTF5MEm4PC=>
SNT-13 MmrwRY51cX[rcnHsJGF{e2G7 MYWxJO69VQ>? M2fCelI1KGh? NIS3RVVKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MlLmNlEyPzB7OEi=
SNT-16 NVHMfHNPSW62aY\pdoFtKEG|c3H5 NYPYRmRFOSEQvF2= NYW2bHN7OjRiaB?= MlvZTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX MUiyNVE4ODl6OB?=
KAI-3 NV\LdY9ZSW62aY\pdoFtKEG|c3H5 NXPmeXh1OSEQvF2= MmHJNlQhcA>? NHTxRVlKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MVeyNVE4ODl6OB?=
SNK-6 NEjHWJJCdnSrdnnyZYwhSXO|YYm= M2LKdVEh|ryP NVjrZnVVOjRiaB?= NUDBWHZEUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MYGyNVE4ODl6OB?=
RAW 264.7 NWTkT3NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHt[oYyODBibl2= MoPQOFghcA>? MX7S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MonZNlI1OjdzNUS=
A375 M4LhbWFxd3C2b4Ppd{BCe3OjeR?= MnjNNVAhdk1? MWmyOEBp MXfJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MYOyN|A4QTB6Mx?=
BLM NGPYXINCeG:ydH;zbZMhSXO|YYm= Mmj2NVAhdk1? NXPqVHcxOjRiaB?= M4fH[Glv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NYD2ZnlHOjNyN{mwPFM>
A375 NFz0W5VCfXSxcHjh[5khSXO|YYm= NXuyOFA5OTBibl2= MXWxNkBp M{PnWmlv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz NYf4NHpuOjNyN{mwPFM>
BLM MYHBeZRweGijZ4mgRZN{[Xl? MXixNEBvVQ>? MWqxNkBp NID3T2tKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> M2HoRlI{ODd7MEiz
H1299 M3rndWFxd3C2b4Ppd{BCe3OjeR?= M2H1XlgxKG6P NUTuTFhFOjRiaB?= MWrEUXNQ NIWx[lVU\W6|aYTpfoV{KE6VQ1zDJINmdGy|IITvJG1USy2mZYLpeoVlKGmFOT3pcoR2[2WmIHHwc5B1d3Orcx?= MYOyOVMzOzZ7Mx?=
Hut-78 MlznSpVv[3Srb36gRZN{[Xl? M4PWW|ExOCCwTR?= M3j4fFI1KGh? MWnEUXNQ NUHVNWJ2TG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMDDlfJBz\XO|aX;u MU[yOVY5OTN|NR?=
H9 NXfkdmdrTnWwY4Tpc44hSXO|YYm= MWWxNFAhdk1? MUeyOEBp MVzEUXNQ NH;ScFJFd3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTFzIHX4dJJme3Orb36= MVKyOVY5OTN|NR?=
HH M3zIeGZ2dmO2aX;uJGF{e2G7 Mo\WNVAxKG6P MknVNlQhcA>? NYrzOXBYTE2VTx?= NES4S5Vld3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTF{IHX4dJJme3Orb36= NFrqOmIzPTZ6MUOzOS=>
Hut-78 NU\mcXdLVWmpcnH0bY9vKEG|c3H5 NYXkXFREOTByIH7N MmO5NlQhcA>? M1TI[GROW09? NXj5SHFlWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mwKS=> MUeyOVY5OTN|NR?=
HH NEjtO|dOcWe{YYTpc44hSXO|YYm= NYK5PZlbOTByIH7N M3vodFI1KGh? MoHkSG1UVw>? M2jWRXJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MTW= NEPBVVIzPTZ6MUOzOS=>
U937 M3jZPGZ2dmO2aX;uJGF{e2G7 M17ZfVExOCCwTR?= NVK5ellHPiCq NF3FUIJKdmS3Y3XzJGlNNThiZYjwdoV{e2mxbjDpckBNWFNvc4TpcZVt[XSnZDDVPVM4KG2jY4LvdIhi\2W| MWiyOVc6OTR5Nx?=
human PBMC NWjxSFB4TnWwY4Tpc44hSXO|YYm= MW[xNFAhdk1? NHnvcpUzPCCq NGnyRnBKdmS3Y3XzJGlNNThicnXs[YF{\Q>? NFXsU4UzPTd7MUS3Oy=>
ES6 M3LkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXVTWM2OD1yLkCwNlEhdk1? MXfTRW5ITVJ?
SK-UT-1 MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTvTWM2OD1yLkG2N{BvVQ>? MYPTRW5ITVJ?
SH-4 NH2xfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMUezJI5O MVrTRW5ITVJ?
TE-9 NWLLNZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv1b3JwUUN3ME2wMlE5OiCwTR?= MVXTRW5ITVJ?
A253 M{jqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XzT2lEPTB;MD6yNFghdk1? MUfTRW5ITVJ?
no-10 NFm3W|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG3TWM2OD1yLkKxJI5O NEL4[2pUSU6JRWK=
MMAC-SF NEfnOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K0fWlEPTB;MD6yNVYhdk1? NEnScZpUSU6JRWK=
A101D MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LLRWlEPTB;MD6yNlUhdk1? M3T4[3NCVkeHUh?=
NTERA-S-cl-D1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzm[FlKSzVyPUCuNlQ{KG6P M1rKSXNCVkeHUh?=
8-MG-BA NELWR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7CVItSUUN3ME2wMlI2KG6P M3r0V3NCVkeHUh?=
KNS-42 MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMkW4JI5O NF[3dJdUSU6JRWK=
LXF-289 NFLpOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMk[5JI5O M4i3ZnNCVkeHUh?=
OVCAR-4 M4TOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHxTWM2OD1yLkK4PUBvVQ>? MofKV2FPT0WU
LOUCY M{LjeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMkmzJI5O MkCxV2FPT0WU
BB65-RCC M2[4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG4TWM2OD1yLkOwOEBvVQ>? MVrTRW5ITVJ?
D-542MG MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfz[XM2UUN3ME2wMlMzQSCwTR?= NWnJNIhDW0GQR1XS
ONS-76 MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vzcmlEPTB;MD6zN{BvVQ>? MlTrV2FPT0WU
BB30-HNC M{G5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHONI9IUUN3ME2wMlM{PSCwTR?= M4HidnNCVkeHUh?=
KS-1 NXfIcIIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi1UVNPUUN3ME2wMlM1KG6P M2TMeXNCVkeHUh?=
A388 NITFbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjvXHRKSzVyPUCuN|U3KG6P MlHIV2FPT0WU
ES8 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nhemlEPTB;MD60JI5O NYLoW2ZWW0GQR1XS
MZ2-MEL MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwNEC3JI5O MlqxV2FPT0WU
HCC2998 NHzoPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwNEGyJI5O NIj3Nm9USU6JRWK=
D-247MG NIXoeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3hfmlKSzVyPUCuOFE{KG6P M4PFOHNCVkeHUh?=
ACN MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHCfnh2UUN3ME2wMlQyPyCwTR?= M1LVT3NCVkeHUh?=
LB2518-MEL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofaTWM2OD1yLkSyOUBvVQ>? NI\DPFdUSU6JRWK=
ES1 M3v3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;RNGlEPTB;MD60N{BvVQ>? MUfTRW5ITVJ?
HCE-T Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S1TWlEPTB;MD60N|khdk1? MojiV2FPT0WU
OS-RC-2 NIXu[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwNESgcm0> MlLyV2FPT0WU
MFH-ino MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLHXlJKSzVyPUCuOFQ{KG6P MVjTRW5ITVJ?
OCUB-M MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvKfnBjUUN3ME2wMlQ1PyCwTR?= M4nUdnNCVkeHUh?=
CP66-MEL MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwNEezJI5O MVfTRW5ITVJ?
LB771-HNC M3raVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfDTWM2OD1yLkS3OEBvVQ>? M3SwW3NCVkeHUh?=
DSH1 M3rUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPiPHlKSzVyPUCuOFghdk1? M3vMXnNCVkeHUh?=
HUTU-80 NIPSc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwNUOzJI5O MV;TRW5ITVJ?
CESS NVvRbnY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXORZlKSzVyPUCuOVM5KG6P MmOxV2FPT0WU
NCI-H747 NFi2V2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILSSFlKSzVyPUCuOVM6KG6P NG\RPFNUSU6JRWK=
HT-144 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjDeWMyUUN3ME2wMlU4PiCwTR?= MWrTRW5ITVJ?
COLO-829 NVf2WFhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwNkG0JI5O M3\hTXNCVkeHUh?=
A4-Fuk MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHKOo46UUN3ME2wMlYzOyCwTR?= MlnqV2FPT0WU
GI-ME-N MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwNkO0JI5O NHPHNG1USU6JRWK=
LB831-BLC NHWwbVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwNkSxJI5O NIj6blNUSU6JRWK=
HOP-62 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13LZWlEPTB;MD62OFchdk1? MXvTRW5ITVJ?
BB49-HNC M4TOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrI[oVKSzVyPUCuOlUzKG6P NYjPXmU2W0GQR1XS
D-336MG NXjScmFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX36PYx5UUN3ME2wMlY2PyCwTR?= M{KybHNCVkeHUh?=
TK10 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3tXWxKSzVyPUCuOlc6KG6P M4D2[3NCVkeHUh?=
Ramos-2G6-4C10 NULqTlI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHVTWM2OD1yLk[5N{BvVQ>? M4TS[3NCVkeHUh?=
LB373-MEL-D MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfGTWM2OD1yLkegcm0> NIPMVVNUSU6JRWK=
SF126 NFz4Z|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK2TWM2OD1yLkewNUBvVQ>? MVrTRW5ITVJ?
UACC-257 NV3oU3hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DCRmlEPTB;MD63NUBvVQ>? M4nNPHNCVkeHUh?=
KINGS-1 NHTRbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r1cGlEPTB;MD63NlIhdk1? M1nHVXNCVkeHUh?=
LS-513 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf5ZnNNUUN3ME2wMlc{QSCwTR?= Mn[3V2FPT0WU
GI-1 NH3rNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwN{[0JI5O M125fXNCVkeHUh?=
ES7 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwN{[2JI5O M{n1OnNCVkeHUh?=
LB2241-RCC MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwOEC0JI5O NVnMSYl4W0GQR1XS
D-263MG M1nzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13heWlEPTB;MD64NFchdk1? MV;TRW5ITVJ?
SW684 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmCwTWM2OD1yLkiyNUBvVQ>? MXrTRW5ITVJ?
ML-2 MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn6yTWM2OD1yLkiyNUBvVQ>? NETXRnFUSU6JRWK=
SK-LMS-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwOEW0JI5O MoPFV2FPT0WU
TE-5 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\LU3ZKSzVyPUCuPFY2KG6P MnH2V2FPT0WU
QIMR-WIL M1rsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjpb5pUUUN3ME2wMlg5QSCwTR?= NWTxPWZ[W0GQR1XS
NCI-H1355 M176V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfSb4JKSzVyPUCuPFk2KG6P MoDoV2FPT0WU
SNB75 NEnJPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwOUGyJI5O NVLOZ2dCW0GQR1XS
RXF393 NYrTZWhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn1dI8xUUN3ME2wMlkyPCCwTR?= Mn7YV2FPT0WU
IST-MEL1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHtTWM2OD1yLkmxO{BvVQ>? M{L1PHNCVkeHUh?=
SF268 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7pTWM2OD1yLkmyN{BvVQ>? MUjTRW5ITVJ?
KALS-1 NIPnZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XBZ2lEPTB;MD65NlUhdk1? MnXXV2FPT0WU
HC-1 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i5S2lEPTB;MD65O|Uhdk1? MlrTV2FPT0WU
SW872 NGLX[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS2TWM2OD1yLkm5OkBvVQ>? NUL4d|k5W0GQR1XS
PSN1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwMEGgcm0> MV;TRW5ITVJ?
TE-1 NWHZSnJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnPdI5KSzVyPUGuNFMhdk1? MUXTRW5ITVJ?
TE-10 M3j1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L4S2lEPTB;MT6wN{BvVQ>? NX\Ed3d7W0GQR1XS
RKO M2jubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f6PGlEPTB;MT6wOkBvVQ>? MV;TRW5ITVJ?
LC-2-ad MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXndFRKSzVyPUGuNFghdk1? NGf3SoFUSU6JRWK=
SK-MM-2 M3fvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTFwMEmgcm0> M3\icXNCVkeHUh?=
VA-ES-BJ NXewN4I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;kbGlEPTB;MT6wPUBvVQ>? M3jGdXNCVkeHUh?=
MZ7-mel MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\xVGJKSzVyPUGuNFkhdk1? M{TEfXNCVkeHUh?=
D-392MG NITUUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHBTWM2OD1zLkGgcm0> NGfqV4dUSU6JRWK=
CCRF-CEM MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwMUOgcm0> M4W0cXNCVkeHUh?=
EM-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzLTWM2OD1zLkG2JI5O NYrDeHJFW0GQR1XS
HAL-01 M1TBN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFmyVolKSzVyPUGuNVghdk1? Mnf6V2FPT0WU
TE-8 NEPCb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2q2XWlEPTB;MT6xPUBvVQ>? NWTRSlBVW0GQR1XS
NCI-H1882 M17YU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnRTYpYUUN3ME2xMlIhdk1? MU\TRW5ITVJ?
Daudi NYS5e2NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXLUZRUUUN3ME2xMlIzKG6P NXzKd4FxW0GQR1XS
BL-41 M2\BWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXDSpREUUN3ME2xMlI2KG6P MnLqV2FPT0WU
SR NV3NRW1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TFUmlEPTB;MT6yOUBvVQ>? MYLTRW5ITVJ?
KM12 NX7uTmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO2N3UxUUN3ME2xMlI4KG6P M4jOOnNCVkeHUh?=
K5 M{HUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor3TWM2OD1zLkK4JI5O Ml\WV2FPT0WU
A3-KAW NWjZOWptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwMkigcm0> NGrZPFFUSU6JRWK=
CMK NFTEPGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH24VZJKSzVyPUGuNlkhdk1? MoG5V2FPT0WU
Calu-6 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrEcpVKSzVyPUGuNlkhdk1? NHj5PI9USU6JRWK=
IST-SL2 M3TreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j4UGlEPTB;MT6zNUBvVQ>? M3LBRXNCVkeHUh?=
OPM-2 NX;WbplLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwM{Ogcm0> NYLwZWlIW0GQR1XS
DU-4475 MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwM{[gcm0> NGjzSnRUSU6JRWK=
ECC12 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT2TWM2OD1zLkO3JI5O M3WxOHNCVkeHUh?=
L-540 NH\iepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHW2UJhKSzVyPUGuN|chdk1? NGDXcmtUSU6JRWK=
CAS-1 NHruT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H1NGlEPTB;MT6zO{BvVQ>? Mnj2V2FPT0WU
PF-382 M{GxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVGzO5NpUUN3ME2xMlQ4KG6P NF7EO|BUSU6JRWK=
LS-411N M{HtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHpUXdKSzVyPUGuOVMhdk1? MYPTRW5ITVJ?
NCI-H69 NWXHZXBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[0OmlEPTB;MT61OEBvVQ>? NF;jfFZUSU6JRWK=
NB12 MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH3e2x2UUN3ME2xMlU3KG6P M2XIenNCVkeHUh?=
HEL Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFwNkGgcm0> NFi2cZVUSU6JRWK=
GCIY NUf4RZBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1POfWlEPTB;MT62NkBvVQ>? MoX1V2FPT0WU
EHEB NVizVWtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDnTWM2OD1zLk[3JI5O MUfTRW5ITVJ?
TGBC1TKB Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwN{Ggcm0> NUjaXWF7W0GQR1XS
KURAMOCHI MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrSTZp5UUN3ME2xMlczKG6P MVXTRW5ITVJ?
U-266 MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TkXWlEPTB;MT63OkBvVQ>? NYDDXHZGW0GQR1XS
LC4-1 MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;NW5lKSzVyPUGuO|khdk1? NIXrXoVUSU6JRWK=
NCI-H2126 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPx[YFIUUN3ME2xMlghdk1? NYPOdYlOW0GQR1XS
NCI-H1092 Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[wWXZVUUN3ME2xMlghdk1? NW\qRVhoW0GQR1XS
GB-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwOEGgcm0> NWW0WohmW0GQR1XS
MV-4-11 NWPYOXZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TTRmlEPTB;MT64NkBvVQ>? MlvLV2FPT0WU
Becker MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPEeVFKSzVyPUGuPFMhdk1? NG\BOFFUSU6JRWK=
MPP-89 NUnDRmtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHJTWM2OD1zLki5JI5O NWPnSIxVW0GQR1XS
BE-13 NUnnPXJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jnRWlEPTB;MT65N{BvVQ>? NW[yU3dtW0GQR1XS
697 NET4WpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HhXWlEPTB;MT65PUBvVQ>? NX\UZ|B3W0GQR1XS
NKM-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zLW2lEPTB;MjDuUS=> NFnIXFBUSU6JRWK=
NB13 NXrV[VRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJibl2= NXzsdIZGW0GQR1XS
LS-123 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml65TWM2OD1{LkCyJI5O NILiPFRUSU6JRWK=
NB17 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jX[WlEPTB;Mj6wOEBvVQ>? Ml2xV2FPT0WU
LAN-6 NGL1UnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJwMEWgcm0> MnLPV2FPT0WU
EW-24 NX;a[oxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjtTWM2OD1{LkC4JI5O MVHTRW5ITVJ?
NOS-1 M3;BfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjPXWljUUN3ME2yMlEyKG6P M{m1VHNCVkeHUh?=
BL-70 NYX5No5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjKS5FNUUN3ME2yMlEzKG6P NXjTSoZPW0GQR1XS
GT3TKB MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XXemlEPTB;Mj6xNkBvVQ>? M{\5VHNCVkeHUh?=
HH M2fMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[5TIlzUUN3ME2yMlE{KG6P M4OwZ3NCVkeHUh?=
KE-37 MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3aeoZKSzVyPUKuNVMhdk1? M3K3NnNCVkeHUh?=
MOLT-4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NECwNlJKSzVyPUKuNVMhdk1? MnixV2FPT0WU
EKVX MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHYNI9KSzVyPUKuNVQhdk1? NGO2d3RUSU6JRWK=
KGN NXHBXHRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkKxTWM2OD1{LkG1JI5O MmjiV2FPT0WU
ES4 NUf1foI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LZUmlEPTB;Mj6xOkBvVQ>? MnzWV2FPT0WU
SJSA-1 NU\UbWxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fzfWlEPTB;Mj6yNUBvVQ>? MUDTRW5ITVJ?
KMOE-2 M2Pw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG1NIZKSzVyPUKuNlMhdk1? M3XEZXNCVkeHUh?=
NB5 NFv3U|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vReGlEPTB;Mj6yO{BvVQ>? NYi3S|dsW0GQR1XS
BC-1 NUDYdotwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTHdYhDUUN3ME2yMlMyKG6P MXXTRW5ITVJ?
NB10 NWLRZpVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\QPGlEPTB;Mj6zNkBvVQ>? M1n6TXNCVkeHUh?=
RPMI-8226 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTwdYp2UUN3ME2yMlM2KG6P M2\ZTHNCVkeHUh?=
SCC-3 M{HOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwM{egcm0> NV61cXZJW0GQR1XS
ARH-77 NU\TWZR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W0fWlEPTB;Mj6zPEBvVQ>? MoPsV2FPT0WU
NCI-H748 NV\zd21[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G5OWlEPTB;Mj6zPUBvVQ>? MljvV2FPT0WU
KU812 M2XjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXIXmpFUUN3ME2yMlQzKG6P MXHTRW5ITVJ?
NCI-H64 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTmO2hiUUN3ME2yMlQ1KG6P NVH5cYJ3W0GQR1XS
NB69 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\u[IRKSzVyPUKuOFYhdk1? MW\TRW5ITVJ?
KNS-81-FD NHHtUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJwNEigcm0> MnHhV2FPT0WU
LB1047-RCC NYX0N|VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjuSVI{UUN3ME2yMlU4KG6P MX\TRW5ITVJ?
EB-3 MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1znOWlEPTB;Mj62OkBvVQ>? NFLaTVNUSU6JRWK=
Mo-T MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJwN{Sgcm0> MnnlV2FPT0WU
EW-16 Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrsco9KSzVyPUKuO|Uhdk1? MVTTRW5ITVJ?
CTV-1 M3rqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f4UGlEPTB;Mj64JI5O NWn4TWNRW0GQR1XS
ETK-1 NFvUemJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\zc3JGUUN3ME2yMlg1KG6P NX3EW5VOW0GQR1XS
C2BBe1 M3LTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnJeJVKSzVyPUKuPFkhdk1? MmH3V2FPT0WU
MOLT-16 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n4RWlEPTB;Mj64PUBvVQ>? NXHHWVNUW0GQR1XS
SW954 NIf4NWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPzSlBrUUN3ME2yMlkhdk1? NEj2foRUSU6JRWK=
HT NUDqSIFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPVTWM2OD1|LkCyJI5O NWC5OIg4W0GQR1XS
KARPAS-299 NUfORmozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DIXGlEPTB;Mz6wOkBvVQ>? MXjTRW5ITVJ?
MONO-MAC-6 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m0ZWlEPTB;Mz6xJI5O NInsc3ZUSU6JRWK=
CGTH-W-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXns[WxIUUN3ME2zMlEhdk1? MUXTRW5ITVJ?
SK-PN-DW MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\ZfWlEPTB;Mz6xOEBvVQ>? NEXiNZNUSU6JRWK=
CW-2 NGTz[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXMTWM2OD1|LkKxJI5O NY\PUI54W0GQR1XS
SK-N-DZ MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nSUGlEPTB;Mz6yOkBvVQ>? M4\2WnNCVkeHUh?=
NEC8 M17mNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\le2FKSzVyPUOuN|Uhdk1? NXXRUnh4W0GQR1XS
LB996-RCC M{nLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTNwNDDuUS=> NH;5fmlUSU6JRWK=
DB MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\pUVdlUUN3ME2zMlQyKG6P MkXSV2FPT0WU
TE-15 NWLUUXlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLsfWFKSzVyPUOuOFMhdk1? NVPPXJpFW0GQR1XS
COR-L88 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTNwNEegcm0> MonMV2FPT0WU
LAMA-84 NHHyUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NImy[IxKSzVyPUOuOFkhdk1? NGTNTXFUSU6JRWK=
MEG-01 Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3THeWlEPTB;Mz60PUBvVQ>? M1\renNCVkeHUh?=
LOXIMVI Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPaTWM2OD1|LkWgcm0> MWPTRW5ITVJ?
RPMI-8402 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvCTXRxUUN3ME2zMlUhdk1? NVu3TmRLW0GQR1XS
KARPAS-45 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTNwNUSgcm0> MX7TRW5ITVJ?
HCC1187 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf0TWM2OD1|LkW0JI5O MkGwV2FPT0WU
MZ1-PC MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Lqe2lEPTB;Mz61OEBvVQ>? MoSwV2FPT0WU
no-11 M4DHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\2O4VoUUN3ME2zMlU2KG6P NVrnVlB2W0GQR1XS
EVSA-T NFjxSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT6dHdKSzVyPUOuOkBvVQ>? M1u2NHNCVkeHUh?=
DJM-1 M{HX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLnTWM2OD1|Lk[zJI5O NVXoS2hRW0GQR1XS
COLO-684 NWDJbm1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTyTWM2OD1|Lk[2JI5O MYfTRW5ITVJ?
NMC-G1 M1HWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vJXWlEPTB;Mz62PEBvVQ>? NUjUTndwW0GQR1XS
LC-1F NH;U[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q0SGlEPTB;Mz63OEBvVQ>? Mmj6V2FPT0WU
RL95-2 M1\UN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j6VGlEPTB;Mz63PUBvVQ>? NEPtWohUSU6JRWK=
COLO-320-HSR NG\YeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP4TWM2OD1|LkmyJI5O NUH0ZVNLW0GQR1XS
RCC10RGB M4fCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTNwOUOgcm0> M1LDPXNCVkeHUh?=
HD-MY-Z M4HMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTNwOUOgcm0> NUnwZXRbW0GQR1XS
NCI-H2141 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fWb2lEPTB;ND6wOUBvVQ>? NI\s[FVUSU6JRWK=
K-562 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTRwMUKgcm0> MXzTRW5ITVJ?
NCI-H1648 NGW2UZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTRwMUOgcm0> NVHjUGxNW0GQR1XS
OMC-1 NUDEVodLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPOc5NQUUN3ME20MlE5KG6P M1O2U3NCVkeHUh?=
LB647-SCLC NYHEPXNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\1bY1WUUN3ME20MlIzKG6P M3PCcnNCVkeHUh?=
TE-12 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTsblVoUUN3ME20MlI2KG6P Ml\iV2FPT0WU
NOMO-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTRwM{Ogcm0> MlTWV2FPT0WU
Raji NEDiTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S2c2lEPTB;ND60OkBvVQ>? MkKyV2FPT0WU
NALM-6 M{PKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrmR5VKSzVyPUSuOFkhdk1? M4fnenNCVkeHUh?=
HL-60 NHfTOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfnTWM2OD12Lk[3JI5O NXfwR2lUW0GQR1XS
IST-SL1 NH3WRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[4TWM2OD12Lk[4JI5O NUS4TlN2W0GQR1XS
MHH-PREB-1 NVPLRnpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfVXmVKSzVyPUSuPFYhdk1? M3roUnNCVkeHUh?=
MHH-NB-11 NF;zWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvvTG9KSzVyPUSuPVEhdk1? NVPU[G83W0GQR1XS
JiyoyeP-2003 NVvzVFBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTs[VV7UUN3ME21JI5O NETzbY1USU6JRWK=
SBC-1 NXHkSXpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vQdmlEPTB;NT6wNUBvVQ>? MYHTRW5ITVJ?
CHP-126 M2LuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfzTWM2OD13LkC2JI5O NVm1OYoyW0GQR1XS
LU-139 MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYGxXI95UUN3ME21MlE{KG6P MVvTRW5ITVJ?
NCI-SNU-5 Mmn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjXb|dJUUN3ME21MlE4KG6P MXPTRW5ITVJ?
SW962 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fs[WlEPTB;NT6yNUBvVQ>? MoXFV2FPT0WU
EW-1 NGHlUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvNOYdKSzVyPUWuN|Ehdk1? M1jhRnNCVkeHUh?=
NCI-H1417 NHTG[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;Kb2lEPTB;NT61NUBvVQ>? NIq5OI9USU6JRWK=
LU-65 NGTZVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P2VWlEPTB;NT64OEBvVQ>? NIT1U5VUSU6JRWK=
D-502MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4r1emlEPTB;Nj6zO{BvVQ>? MXLTRW5ITVJ?
BC-3 M3[1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTZwNkGgcm0> MmH3V2FPT0WU
GDM-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITjR|RKSzVyPU[uO|chdk1? NHHlflVUSU6JRWK=
NCI-H2196 M2\O[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rmUGlEPTB;Nj64JI5O Mm\aV2FPT0WU
NB1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1z1RmlEPTB;Nj64PEBvVQ>? NHLrZWpUSU6JRWK=
NCI-H345 M4TrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnvbXF5UUN3ME23MlIhdk1? MkT4V2FPT0WU
SU-DHL-1 MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrTPJNKSzVyPUeuNlQhdk1? MkjOV2FPT0WU
JVM-2 NUmwN3B4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHnTWM2OD15LkK4JI5O NUC5OmYzW0GQR1XS
LU-134-A M{fuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrhNmNKSzVyPUeuN|khdk1? NIHm[HhUSU6JRWK=
NCI-H1694 MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPNTWM2OD15LkW4JI5O Mn7XV2FPT0WU
NCI-SNU-16 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzmTWM2OD15Lk[1JI5O M{\yT3NCVkeHUh?=
L-363 M{K5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnLNmNKSzVyPUeuO{BvVQ>? NYKyeW9OW0GQR1XS
KG-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX6[YdKSzVyPUeuPVQhdk1? NH[3OpBUSU6JRWK=
MN-60 NHP1XYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;DOoVsUUN3ME24MlE1KG6P NXrZOI1CW0GQR1XS
NB6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LR[WlEPTB;OD60PEBvVQ>? M3O1RnNCVkeHUh?=
MLMA MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPCTWM2OD16Lki1JI5O NIXkVpRUSU6JRWK=
ATN-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnGfIJYUUN3ME24Mlg6KG6P MYPTRW5ITVJ?
SK-NEP-1 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[xSWVkUUN3ME25MlAyKG6P MXfTRW5ITVJ?
DMS-114 MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHvW2lKSzVyPUmuOlIhdk1? Mk\rV2FPT0WU
CTB-1 NWGxZmtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTZTWM2OD17Lk[3JI5O NVfVTGZpW0GQR1XS
NCI-H2081 NYDqWG9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[zTWM2OD1zMD6wPUBvVQ>? NX3ESGxFW0GQR1XS
ES5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFyLkO4JI5O NGLkWoxUSU6JRWK=
HCC1599 NILnRZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q0d2lEPTB;MUGuPVEhdk1? NImwXIlUSU6JRWK=
NCI-H23 Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fmcWlEPTB;MUKuNVIhdk1? NWnsR21YW0GQR1XS
NCI-H1581 NF7JXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjHTHdKSzVyPUGyMlI5KG6P M1f3Z3NCVkeHUh?=
JVM-3 NUDPOGtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLzbnJjUUN3ME2xNk46QSCwTR?= NWH1Wo1uW0GQR1XS
NCI-SNU-1 NFrP[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHKfHFnUUN3ME2xN{4yQSCwTR?= NX\uNVdwW0GQR1XS
NB7 NGDrWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLqTWM2OD1zNT65NkBvVQ>? NEjGTYFUSU6JRWK=
JAR NVHseY5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PlPGlEPTB;MU[uNVMhdk1? MWXTRW5ITVJ?
TGW MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTLTWM2OD1zNj60PEBvVQ>? NV;sRW53W0GQR1XS
U-87-MG NEjUeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvQNGJZUUN3ME2xOk44PiCwTR?= MVHTRW5ITVJ?
NCI-H1436 Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX2NHdKSzVyPUG3MlAyKG6P MYPTRW5ITVJ?
GOTO M1z0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[4UnBKSzVyPUG3MlA3KG6P M1y3THNCVkeHUh?=
COLO-800 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i2bGlEPTB;MUeuOlQhdk1? NVTKeVRSW0GQR1XS
MFM-223 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF5LkmxJI5O MXPTRW5ITVJ?
EW-18 M3ryUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPiUHpKSzVyPUG3Mlk3KG6P NUnpc2ZiW0GQR1XS
NB14 NWPwdJBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF5Lkm4JI5O NHK5TItUSU6JRWK=
EB2 NFH2XXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv6TWM2OD1zOD6wPEBvVQ>? NITse5VUSU6JRWK=
EoL-1- NH3QdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX1VGdKSzVyPUG4MlMyKG6P M3vuT3NCVkeHUh?=
NCCIT NH7SZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHVTWM2OD1zOD6zOkBvVQ>? NVH4SHl3W0GQR1XS
DG-75 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rKOGlEPTB;MUiuOlEhdk1? MWDTRW5ITVJ?
HCC2218 M3XBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrKTWM2OD1zOT61JI5O NEe2ZWlUSU6JRWK=
TE-6 NVzj[Vg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi2TWM2OD1{MD6wPEBvVQ>? NWTzeHlRW0GQR1XS
SF539 NW\DTHd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJyLk[3JI5O M{fm[3NCVkeHUh?=
NCI-H446 NGqyW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjE[HdKSzVyPUKxMlE5KG6P M3H5WHNCVkeHUh?=
IST-MES1 NXi2UW5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK2bmFKSzVyPUKyMlc4KG6P NIHEO3lUSU6JRWK=
NCI-H82 NHrKSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\iTWM2OD1{Mz6wNkBvVQ>? MlTKV2FPT0WU
HCC2157 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXPUXRTUUN3ME2yN{4yOyCwTR?= MoHHV2FPT0WU
EW-12 M4PWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnLfJZKSzVyPUKzMlE4KG6P MnzwV2FPT0WU
SIMA MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\FTWM2OD1{Mz6zPEBvVQ>? M2LWWXNCVkeHUh?=
DOHH-2 NEDWfnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH5cGgzUUN3ME2yN{41PSCwTR?= NGTUS3NUSU6JRWK=
IM-9 NHrBfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXxTWM2OD1{Mz61OEBvVQ>? NGq3SG1USU6JRWK=
EC-GI-10 NWLTTIRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7QW4dnUUN3ME2yOE4zOyCwTR?= NETxclZUSU6JRWK=
HDLM-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13KOGlEPTB;MkSuOVQhdk1? M4\6fXNCVkeHUh?=
LS-1034 NWfsS405T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DtR2lEPTB;MkWuO|Uhdk1? NFjRZ41USU6JRWK=
REH NF:2PZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[4TWM2OD1{Nj60NUBvVQ>? MoDQV2FPT0WU
LU-165 NFexXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;FWJlKSzVyPUK2MlczKG6P MnzVV2FPT0WU
NH-12 MoK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW1TWM2OD1{Nz62O{BvVQ>? NYfXeZZlW0GQR1XS
WSU-NHL M1nmcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\WSZdKSzVyPUK4MlM6KG6P NXPVVZBFW0GQR1XS
ECC4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\3TGlEPTB;MkiuO|khdk1? MnLuV2FPT0WU
OCI-AML2 NGfiN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS5W3pTUUN3ME2yPU43QSCwTR?= MW\TRW5ITVJ?
EW-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFflNYlKSzVyPUOwMlU6KG6P MkTvV2FPT0WU
NCI-H526 NXf4THNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLHTWM2OD1|Mj61OEBvVQ>? M1ztSHNCVkeHUh?=
NCI-H719 M1fKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTib24zUUN3ME2zOE4{OSCwTR?= MmH6V2FPT0WU
KARPAS-422 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLVW5NKSzVyPUO1MlA1KG6P NVzReoNYW0GQR1XS
SK-MEL-1 NUHMVmc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTN3LkG3JI5O MnqyV2FPT0WU
ES3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTt[IF5UUN3ME2zOU4yQSCwTR?= MXHTRW5ITVJ?
UACC-812 NX7GeY17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXiXnF2UUN3ME2zOU41PCCwTR?= MnO3V2FPT0WU
C8166 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTN3Lkegcm0> NVyzeWx6W0GQR1XS
MDA-MB-134-VI M4DFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnZOWlKSzVyPUO1Mlg4KG6P NHnDT2FUSU6JRWK=
D-283MED NILDc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj5RnhtUUN3ME2zO{44QSCwTR?= NHLRbGFUSU6JRWK=
SHP-77 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTxWFRKSzVyPUO4MlA{KG6P M1vYbHNCVkeHUh?=
NCI-H2227 NWXTOpk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmflTWM2OD12MD60PUBvVQ>? NHrIZ4tUSU6JRWK=
SKM-1 NIPwNnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDadGg{UUN3ME20Nk43OyCwTR?= NGLRZo5USU6JRWK=
L-428 M2POVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HkV2lEPTB;NEOuPFYhdk1? M3TSWHNCVkeHUh?=
RPMI-6666 MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXBTWM2OD12NT64PUBvVQ>? MWHTRW5ITVJ?
NCI-H716 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfqdo9KSzVyPUS4MlgyKG6P M1LRW3NCVkeHUh?=
DMS-79 MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;QdmJKSzVyPUWwMlcyKG6P NGjO[JBUSU6JRWK=
RS4-11 NEj2[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jnWGlEPTB;NUCuPFghdk1? MWnTRW5ITVJ?
NCI-H720 MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPBUFhKSzVyPUWxMlEyKG6P NVS5SGZyW0GQR1XS
MC-CAR NFmwOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPFXGdQUUN3ME21NU42OiCwTR?= MXHTRW5ITVJ?
TALL-1 M1nTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTV|LkmxJI5O M4LmSXNCVkeHUh?=
NCI-N87 NUj0cHFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLmS2ZKSzVyPUW0MlE5KG6P NV3afYpMW0GQR1XS
P30-OHK NEDkTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DNd2lEPTB;NUSuOlEhdk1? MmLqV2FPT0WU
LP-1 NWjQeGdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP4SXFKSzVyPU[xMlI5KG6P MX3TRW5ITVJ?
YT NGDzUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYCwSJNIUUN3ME22NU45KG6P NXfkS|F5W0GQR1XS
MRK-nu-1 Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\uS2lEPTB;NkGuPFIhdk1? NIGzcWtUSU6JRWK=
BT-474 NIC0VVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnvTWM2OD14NTDuUS=> NIexVppUSU6JRWK=
NCI-H322M MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[3WHRKSzVyPU[2MlEyKG6P NFv4XZRUSU6JRWK=
NCI-H128 MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTd2Lke3JI5O MVXTRW5ITVJ?
KMS-12-PE MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXjbZZsUUN3ME23Ok4zPCCwTR?= MoDlV2FPT0WU
KP-N-YS NGjrdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\ZTWM2OD15Nj63OEBvVQ>? MUDTRW5ITVJ?
ALL-PO NHrQUI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTd5Lk[2JI5O NXjPTlJEW0GQR1XS
EW-13 Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2CxOGlEPTB;N{euO|Yhdk1? NHntd4tUSU6JRWK=
EW-11 Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTd6LkWyJI5O NFrHRVRUSU6JRWK=
SK-N-FI M{fnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NESwbIZKSzVyPUiwMlIhdk1? NXrae443W0GQR1XS
CAL-148 MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTXUlJHUUN3ME24NU45PCCwTR?= MnH3V2FPT0WU
RL NYP1cHdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTsWWdCUUN3ME24Ok4xQSCwTR?= NIjqdVZUSU6JRWK=
AM-38 M{jSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HW[WlEPTB;OEiuNFghdk1? M{XCSXNCVkeHUh?=
RH-1 NIXSOmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDUTWM2OD17OT64OUBvVQ>? MnTiV2FPT0WU
NCI-H1770 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT5d5lHUUN3ME2xNFIvPDlibl2= M2P1PXNCVkeHUh?=
SIG-M5 MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT2OGNKSzVyPUGwOU4xPiCwTR?= NGDZW49USU6JRWK=
GR-ST NYe1[5c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3RO4ZKSzVyPUGxN{4{PCCwTR?= M1PxZnNCVkeHUh?=
ST486 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1WwWWlEPTB;MUG0MlA3KG6P NFnZflNUSU6JRWK=
NCI-H1650 MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C1ZWlEPTB;MUG1MlI6KG6P MVHTRW5ITVJ?
MHH-CALL-2 NVHMTHNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofOTWM2OD1zMUWuO{BvVQ>? NUXXRm1kW0GQR1XS
BV-173 NVW3fo9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF{Mj63NUBvVQ>? NXvyd4ZGW0GQR1XS
MC116 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF2OD64OUBvVQ>? Ml\MV2FPT0WU
NCI-H524 NIDZO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\6WmxCUUN3ME2xOVkvOSCwTR?= MonGV2FPT0WU
SCLC-21H M4DNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G3e2lEPTB;MUW5MlQyKG6P M4DzNnNCVkeHUh?=
NCI-H1304 NVPUUlFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK1Z5hKSzVyPUG2PU4zOSCwTR?= NWHWN3U{W0GQR1XS
NCI-H510A MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHWTWM2OD1zOEWuN|chdk1? MYPTRW5ITVJ?
NCI-H209 M{Ta[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PpcGlEPTB;MUm2MlUzKG6P MkTsV2FPT0WU
KM-H2 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF7Nz6wOUBvVQ>? NIrhfWNUSU6JRWK=
NCI-H1395 Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;Tc4pKSzVyPUKxNE4yOyCwTR?= NXrKPIxmW0GQR1XS
NCI-H1155 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJ|MD6zNkBvVQ>? MnvOV2FPT0WU
COR-L279 M{TtfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\XTWM2OD1{NUKuNVchdk1? MWLTRW5ITVJ?
NCI-H1299 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ4MT63NUBvVQ>? NIC4SFdUSU6JRWK=
EW-22 MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvOOYRKSzVyPUK2N{44PSCwTR?= MmTEV2FPT0WU
SK-MEL-2 MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmw[|FPUUN3ME2yPFEvQSCwTR?= NHzXTWNUSU6JRWK=
KASUMI-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJ6Mz6wOUBvVQ>? NU\IU4RqW0GQR1XS
NCI-H187 NFzTbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnONG82UUN3ME2yPFcvODhibl2= MWHTRW5ITVJ?
NCI-H2171 NFrWXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T3dGlEPTB;Mki4MlkzKG6P NEHneI1USU6JRWK=
LNCaP-Clone-FGC M2\OOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJ7NT6yOkBvVQ>? NVvldpQ6W0GQR1XS
NCI-H1522 NIXtNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTidmQyUUN3ME2zNFcvODVibl2= NFO5U2lUSU6JRWK=
SCH NIrwTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7aXZkxUUN3ME2zNlIvOjJibl2= NX6xV5dRW0GQR1XS
THP-1 M{Tn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN{Mj62JI5O MUjTRW5ITVJ?
SNU-C1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTN4Mj6wPUBvVQ>? M13EbXNCVkeHUh?=
CA46 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O4NGlEPTB;M{ezMlY{KG6P MnjuV2FPT0WU
NCI-H1963 Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojjTWM2OD1|OE[uNVkhdk1? NU\5eoRUW0GQR1XS
DEL NVTROXBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknOTWM2OD1|OUGuNlchdk1? M2G2bnNCVkeHUh?=
TUR Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXvTWM2OD1|OU[uOlEhdk1? M{\kW3NCVkeHUh?=
NCI-H226 NH;MdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfETWM2OD12MEOuNlMhdk1? NULFWWNRW0GQR1XS
COLO-668 NHzMfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPmTWM2OD12MEOuOVchdk1? NX\ISnFRW0GQR1XS
CPC-N Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;CSGVRUUN3ME20NFMvPzdibl2= M4nMN3NCVkeHUh?=
NCI-H889 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTR4MT65NkBvVQ>? Mli0V2FPT0WU
J-RT3-T3-5 NVT2OmR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnWNHlKSzVyPUWzNk42PyCwTR?= Mkf5V2FPT0WU
MSTO-211H M4TqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTV5ND6yOkBvVQ>? NUf3SHhjW0GQR1XS
SCC-15 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vjW2lEPTB;Nk[3MlQ4KG6P MnnkV2FPT0WU
SUP-T1 NHO0XmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nidGlEPTB;Nki2MlA1KG6P NF\BdJhUSU6JRWK=
DMS-153 NHrzO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXXNY53UUN3ME23OFYvQDNibl2= M3f1eXNCVkeHUh?=
MS-1 NIC3fFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1u5NmlEPTB;N{W5MlQzKG6P MmLzV2FPT0WU
TC-YIK MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPFSYxKSzVyPUe4NU4xOSCwTR?= M4WwZXNCVkeHUh?=
RPMI-8866 Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3GSWFKSzVyPUGwNFYvOjhizszN M{S0WnNCVkeHUh?=
KY821 M3XMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vHc2lEPTB;MUCzOk4xPCEQvF2= NUjGWFY4W0GQR1XS
P31-FUJ MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn0TWM2OD1zMUGyMlc2KM7:TR?= MlLiV2FPT0WU
COLO-824 NH\4NlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF{NkGuO|gh|ryP Mn3qV2FPT0WU
U-698-M NYXBS2U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr2PIZFUUN3ME2yNlYzNjF3IN88US=> M13k[nNCVkeHUh?=
TE-441-T MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS1TWM2OD1{NUKxMlch|ryP NVPKNI9rW0GQR1XS
IMR-5 NEnjeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYWzWVlRUUN3ME2zOFA6NjZ{IN88US=> MmP1V2FPT0WU
NCI-H1838 M{DzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f6PWlEPTB;NEG4Ok4{OiEQvF2= NHS4R3pUSU6JRWK=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
phospho-PERK / ATF-4; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

GRP-78 / GADD-34; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-12 / pro-caspase-3; 

PubMed: 15509775     


MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-9; 

PubMed: 15509775     


UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin.

p-IκBα / IκBα; 

PubMed: 20335171     


PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. 

COX-2 / cIAP2; 

PubMed: 24085292     


NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times.  Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin. 

15509775 20335171 24085292
Immunofluorescence
Vimentin; 

PubMed: 19010849     


ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

Ubiquitin; 

PubMed: 19010849     


IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

19010849
Growth inhibition assay
Cell viability ; 

PubMed: 20571067     


A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (**P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). **P < 0.01.

20571067
ELISA
IL-8; 

PubMed: 24085292     


NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.

24085292
In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]
- Collapse

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]
- Collapse
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]
- Collapse
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4
CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341
Smiles CC(C)CC(NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03993262 Not yet recruiting Drug: Bortezomib|Drug: Placebo Autoimmune Encephalitis Jena University Hospital February 1 2020 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

selleck catalog

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

  • Classic Proteasome Inhibitor

    ONX-0914 (PR-957) : Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

Related Proteasome Products

  • VR23 New

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin New

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively. Calpeptin attenuates apoptosis and intracellular inflammatory changes in muscle cells.

  • Marimastat (BB-2516) New

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis.

  • Ixazomib (MLN2238)

    Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Ixazomib (MLN2238) induces autophagy. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • Ixazomib Citrate (MLN9708)

    Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Ixazomib (MLN2238) induces autophagy. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID